Disease · MONDO_0004555

kidney angiomyolipoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kidney angiomyolipoma. Diseases, record MONDO_0004555. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004555

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kidney angiomyolipoma; Open Targets
Open Targets ID: MONDO_0004555; Open Targets
Other names: angiomyolipoma of kidney, angiomyolipoma of the kidney, renal angiomyolipoma; Open Targets
Disease Ontology: DOID:8411; Disease Ontology
NCI Thesaurus: C3888; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 4 drugs, from DailyMed; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EVEROLIMUS	CHEMBL1908360	Small molecule	Approval	DailyMed	5	3	3	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IVONESCIMAB	CHEMBL6068451	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Approval	https://conductscience.org/library/genes/2280	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00789828	Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)	Phase 3	117	2012-05-01	Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03525834	Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.	Phase 4	40	2021-09-09	Renal Angiomyolipoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00126672	RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS	Phase 2	36	2022-04-25	Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT06683846	Ivonescimab in the Treatment of Multiple Advanced Tumors	Phase 2	400		Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors	IVONESCIMAB	Its record names the disease	ClinicalTrials.gov
NCT00490789	Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM	Phase 2	14		Tuberous Sclerosis, Lymphangioleiomyomatosis	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT05252585	A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)	Phase 4	10		Renal Angiomyolipoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02104011	Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers	Phase 2	2		Renal Angiomyolipomas, Tuberous Sclerosis	PROPRANOLOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30053159	DERIVED	1	PubMed
29023494	DERIVED	1	PubMed
27351628	DERIVED	1	PubMed
26858193	DERIVED	1	PubMed
25682485	DERIVED	1	PubMed
25456370	DERIVED	1	PubMed
24729041	DERIVED	1	PubMed
23733802	DERIVED	1	PubMed
23437092	DERIVED	1	PubMed
23158522	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004555

GET https://conductscience.org/api/diseases/v1/MONDO_0004555/drugs

API reference For AI assistants